相关实验视频
Updated: Jun 18, 2025

06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
10.6K
基于天然产品的2型糖尿病和心血管疾病的治疗潜力
Dharmsheel Shrivastav1, Satyam Kumar Kumbhakar2, Shivangi Srivastava3
1Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur 303002, Rajasthan, India.
World journal of diabetes
|August 5, 2024
概括
天然产品在治疗2型糖尿病 (T2D) 和心血管疾病 (CVD) 方面表现有前途. 它们提供抗氧化和抗炎功效,可能降低这两种疾病的风险.
科学领域:
- 综合医学是一个整体的医学.
- 营养科学 营养科学
- 心血管健康 心血管健康
背景情况:
- 2型糖尿病 (T2D) 和心血管疾病 (CVD) 具有共同的风险因素和发病因子.
- 这两种疾病都是全球发病率和死亡率的主要原因.
- 自然产品为T2D和CVD提供了潜在的预防和治疗策略.
研究的目的:
- 批判性地评估天然产品在治疗T2D和冠状动脉疾病 (CAD) 中的治疗潜力.
主要方法:
- 使用特定关键词对PubMed的系统文献搜索.
- 专注于随机对照试验 (RCT),检查天然产品对血糖控制,氧化应激和抗氧化剂水平的影响.
- 包括9个符合预先定义的纳入标准的RCT.
主要成果:
- 一些天然产品,包括美国人参,芝麻油和可可黄,有效降低血糖和血压.
- 鱼油,亚麻油,尼格拉油和Terminalia chebula显示出抗炎作用,改善了脂质配置和内皮功能.
- 梅丽莎花 (Melissa officinalis) 和白提取物分别显示出预防糖尿病和改善血糖控制的潜力.
结论:
- 自然产品具有显著的抗氧化,抗炎和抗血管性质.
- 这些特性使得它们成为治疗CAD的有希望的治疗选择.
- 补充天然产品可能会降低患CAD的风险.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Diabetes: Management and Pharmacotherapy
247
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
247
Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
Carbohydrate Metabolism
10.9K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
10.9K
Oral Hypoglycemic Agents: Biguanides and Glitazones
185
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
185
Glucagon-like Receptor Agonists
311
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
311

